Our strength lies in our dynamic product pipeline. Present internal pipeline products, all of which are available for mid to late stage licensing, include new drugs (NDA's) designed to extend the life of, improve upon or replace existing branded drugs, and bio-equivalents (ANDA's) of successful branded controlled-release drugs. Based upon our track record, the chance of successful development of these products is excellent.
We have a strong track record in designing and developing controlled-release drug products for our clients. Seven bio-equivalent controlled release products and dosages in the U.S. market today were designed and developed by our scientists and have enjoyed strong sales in the demanding U.S. market.
For more information contact Business Development at email@example.com.